Biocontainment Research Support Services Core

生物防护研究支持服务核心

• 批准号: 10793910
• 负责人: Karen Marie Dobos
• 金额: $ 77.88万
• 依托单位: COLORADO STATE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-08-18 至 2028-07-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10793910
• 关键词: Acute; Animal Model; Animals; Biocompatible Materials; Biological; Biological Assay; Bioreactors; Cells; Centers of Research Excellence; Characteristics; Chemicals; Clinical Research; Clinical Trials; Collection; Colorado; Cryoultramicrotomy; Cyclic GMP; Databases; Development; Diagnostic; Dissection; Domestic Animals; Emerging Communicable Diseases; Equipment and supply inventories; Fresh Tissue; Growth; Health system; Histology; Human; Immunity; In Vitro; Infection; Infrastructure; Investments; Laboratories; Laboratory Animals; Mass Spectrum Analysis; Microbial Physiology; Modeling; Outcome; Pathogenesis; Pathology; Preparation; Process; Production; Proteomics; Qualifying; Reagent; Recording of previous events; Reproducibility; Research; Research Personnel; Research Support; Resource Development; Resources; Sampling; Series; Services; Study models; System; Technology; Testing; Universities; Vaccines; Viral; Workforce Development; biodefense; biosafety level 3 facility; cGMP production; cell bank; design; emerging pathogen; expectation; forging; health economics; improved; in vivo; innovation; laser capture microdissection; manufacturing scale-up; mass spectrometric imaging; metabolomics; molecular mass; multidisciplinary; new technology; pandemic pathogen; pandemic potential; pathogen; pathogenic bacteria; pathogenic virus; pre-clinical; preclinical study; preservation; programs; response; scale up; screening; socioeconomics; spillover event; synergism; tool; transcriptomics; transmission process; vaccine trial; vaccinology

Project Summary: RMRBL UC7 Core 3 The Rocky Mountain Regional Biocontainment Laboratory (RMRBL) was conceived concomitant with a Research Center for Excellence in Biodefense / Emerging Infectious Diseases. The outcome of these synergized investments in infrastructure and research was a multidisciplinary team of investigators and core research services. The RMRBL’s ability to respond to emerging and persistent pathogen threats are due to our collective understanding of pathogen characteristics, pathogenesis of infection, immunity and host range. Our prolific history of rapid response to high consequence pathogens posing a threat to public and socioeconomic health is due not only to the diverse strengths of the resident investigator teams, but also our ability to conduct these important studies in BSL3 facilities. Specifically, the CSU RMRBL has strengths in defining and optimizing in vitro culture conditions for pathogens and pathogen inactivation, establishing the requisite animal models to investigate wildlife and domestic animal spillover events and reservoir potential, and vaccine models using both viable and inactivated infectious materials produced in vitro. Further, the CSU RMRBL has expertise in cutting-edge technologies to study microbial physiology and animal models; such as conducting proteomic and metabolomics mass spectrometry analyses, detailed histopathologic analyses using spatial transcriptomics and AI-driven quantitative pathology scoring. Lastly, our collective research teams have established programs for supplying biological reagents that can be robustly used for animal and human clinical research, including inactivated biomaterials that can be safely and reproducibly used outside the BSL3. In this Core, we culminate our collective strengths into one Biocontainment Research Resources Core within the BSL3 facilities of the RMRBL. This resultant pathogen characterization core devises our capacity through independent and highly interactive aims; Aim 1: Natural reservoirs of infection and spillover threat for pathogens of pandemic potential; Aim 2: Reagents and models for vaccine and diagnostics studies for pathogens of pandemic potential; and Aim 3: Pathogen:Host materials processing for molecular mass spectrometry imaging and single cell ‘omics analyses. The RMRBL BSL3 Pathogen Characterization core provides opportunities to synergize activities, expand our resources across the RBL network and to additional partners, forge new technologies within the RMRBL BSL3, and ultimately improve our ability to adapt and rapidly deliver research resources acutely responsive to pathogens possessing a threat to our health systems.

项目摘要：RMRBL UC7核心3 落基山地区生物疗养实验室（RMRBL）被构想 具有生物幻想 /新兴传染病的卓越研究中心。这 这些在基础设施和研究方面的协同投资的结果是多学科 研究人员和核心研究服务团队。 RMRBL回应新兴的能力 持续的病原体威胁是由于我们对病原体的集体理解 特征，感染的发病机理，免疫学和宿主范围。我们的快速历史 对高后果病原体对公共和社会经济健康构成威胁的反应是 不仅是由于居民调查员团队的不同优势，而且是由于我们的能力 在BSL3设施中进行这些重要研究。具体而言，CSU RMRBL具有优势 定义和优化病原体和病原体失活的体外培养条件， 建立必要的动物模型来调查野生动植物和家养动物spilover 事件和储层潜力，以及使用可行和不活跃感染的疫苗模型 体外生产的材料。此外，CSU RMRBL在尖端技术方面具有专业知识 研究微生物生理和动物模型；例如进行蛋白质组学和 代谢组学质谱分析，使用空间的详细组织病理学分析 转录组学和AI驱动的定量病理评分。最后，我们的集体研究团队 已经建立了提供可用于动物的生物试剂的程序 和人类的临床研究，包括可以安全的生物材料的灭活的生物材料 在BSL3外可重复使用。在这个核心中，我们最终将我们的集体优势最终形成一个 RMRBL BSL3设施中的生物疗法研究资源核心。这个结果 病原体表征核心通过独立和高度互动来设计我们的能力 目标；目的1：感染的自然储藏和大流行病原体的Spilover威胁 潜在的;目标2：用于病原体的疫苗和诊断研究的试剂和模型 大流行可能性;和目标3：病原体：分子质量的宿主材料处理 光谱成像和单细胞'OMICS分析。 RMRBL BSL3病原体表征核心提供了协同活动的机会， 在RBL网络上扩展我们的资源，并向其他合作伙伴，Forge New Technologies 在RMRBL BSL3中，最终提高了我们适应和快速提供研究的能力 资源对对我们的卫生系统的威胁有敏感的病原体反应。